Novo Nordisk
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$40.28
FAIR PRICE
$60.66
MARGIN
$20.38
NOW AVAILABLE
Get notified when NVO's fair price changes
Push notifications when NVO's valuation shifts. Available on iOS and Android.
FPI RATING
Strong profitability and high-quality fundamentals across the board.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$48.53
Fair price × 0.80
DISTANCE
20.5%
Price to entry level
At the current price of $40.28, NVO trades 20.5% below the conservative entry level of $48.53. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate NVO's fair price
Novo Nordisk's fair price of $60.66 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $40.28, NVO trades 50.6% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting NVO's risk profile.
RELATIVE · 30%
Comparing NVO's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for NVO, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate NVO's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for NVO.
Explore on BuliosFAQ
What is the fair price of NVO?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Novo Nordisk is $60.66. At the current market price of $40.28, NVO trades 50.6% below its calculated fair value.
Is NVO overvalued or undervalued?+
Novo Nordisk is currently undervalued based on our valuation model. The stock trades at $40.28, which is 50.6% below the fair price of $60.66. The P/E ratio of 11.0x is a key metric in the valuation.
What is the margin of safety for NVO?+
With a 20% margin of safety applied to the fair price of $60.66, the conservative entry level for NVO is $48.53. At the current market price of $40.28, the stock trades 20.5% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is NVO's fair price updated?+
We update fair price calculations for NVO daily after market close. The current fair price of $60.66 incorporates the latest market data and sector multiples.
What factors affect NVO's fair price calculation?+
NVO's fair price of $60.66 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 11.0x, ROE of 67.0%, and dividend yield of 3.30%.
Is NVO a good buy right now?+
At $40.28, NVO trades 50.6% below our fair value estimate of $60.66. The stock is currently undervalued. ROE stands at 67.0% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does NVO pay dividends?+
NVO has a dividend yield of 3.30%.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.